The LymeX Diagnostics Prize is a competition to accelerate the development of Lyme disease diagnostics. The ultimate goal of the multiphase competition is to nurture the development of these diagnostics toward Food and Drug Administration clearance.
Phase 1 called on scientific, technical, and clinical experts to submit innovative methods for detecting active Lyme disease infections in people. Phase 2 invited the 10 Phase 1 winners to participate in a virtual accelerator that offered the cohort access to virtual learning, mentorship, biorepository subject matter expertise, and networking opportunities designed to help the teams progress toward FDA review.
In Phase 3, six teams received technical assistance and planned clinical performance studies toward validating their proposed solutions. In Phase 4, invited teams will receive technical assistance to execute their clinical performance studies and submit their diagnostics for FDA clearance.
The LymeX Diagnostics Prize is made possible thanks to a more than $10 million pledge from the Steven & Alexandra Cohen Foundation.